A new book shows how Johnson & Johnson has pushed misleading narratives and suppressed inconvenient findings to sell its ...

For generations of Americans the Johnson & Johnson brand has been a beloved one, as quintessentially American as baseball and apple pie. Its baby shampoo No More Tears has been a fixture in bathrooms, ...

An investigative history of the scandal-plagued company shines a light on a health care industry riddled with corruption and criminality.

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

A Lawrence woman has been charged in Johnson County with distributing a drug that allegedly caused a 53-year-old woman’s ...

Commissioner Makary touts dubious evidence on talcum powder at a rushed hearing.

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...

Opioid use continues to be a significant problem felt broadly in our community,” a city officials told the City Council this ...

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

Johnson & Johnson recently garnered attention when the FDA's Oncologic Drugs Advisory Committee voted favorably on the use of DARZALEX FASPRO® for high-risk smoldering multiple myeloma.